Why DDI Magnitude Changes Over Time
A drug interaction need not reach its full magnitude as soon as the perpetrator drug is started, and it need not disappear as soon as that drug is stopped. Reversible inhibition can track inhibitor concentration relatively quickly, but enzyme inactivation and induced enzyme synthesis change the amount of active enzyme over time. The timing depends on both the perpetrator drug and enzyme turnover.
This distinction matters when interpreting early measurements, choosing the duration of a DDI study, and estimating how long an interaction may persist after treatment ends. The models here describe enzyme abundance or activity relative to baseline, then relate that activity to victim-drug clearance. They do not replace a full concentration-time model when clearance changes substantially during a victim-drug dosing interval.
Deriving Enzyme Onset and Recovery
The model assumes first-order enzyme degradation, synthesis that is specified by \(s(t)\), and inactivation that is proportional to the amount of active enzyme. It also assumes that baseline enzyme abundance is stable: baseline synthesis equals baseline degradation. For mechanism-based inactivation, a common concentration-dependent representation is \(k_{\mathrm{inact}}(t)=k_{\mathrm{inact,max}}I_u(t)/(K_I+I_u(t))\), where \(I_u(t)\) is unbound perpetrator concentration and \(K_I\) is the concentration producing half-maximal inactivation rate. This expression is a model assumption, not a universal law; the parameters should be supported by suitable data.
Under constant perpetrator exposure, both \(s\) and \(k_{\mathrm{inact}}\) are constant. Write \(k_{\mathrm{obs}}=k_{\mathrm{inact}}\). At steady state, enzyme activity no longer changes, so setting the derivative to zero gives the steady-state activity. The deviation from that value decays exponentially, as shown by rearranging the differential equation.
For induction alone, \(k_{\mathrm{obs}}=0\), and a constant synthesis multiplier \(s\) gives \(e_{\mathrm{ss}}=s\). Activity approaches that value at rate \(k_{\mathrm{deg}}\). For inactivation alone, \(s=1\), so the steady-state activity is below baseline. The approach rate is \(k_{\mathrm{deg}}+k_{\mathrm{obs}}\): inactivation removes active enzyme in addition to normal degradation.
After a perpetrator effect has stopped, suppose enzyme inactivation is absent and synthesis has returned to baseline, \(s=1\) and \(k_{\mathrm{obs}}=0\). Starting from activity \(e_0\), recovery follows $$ e(t)=1+(e_0-1)\exp(-k_{\mathrm{deg}}t). $$ The enzyme half-life is \(\ln(2)/k_{\mathrm{deg}}\). It is the half-life of the excess or deficit from baseline during this recovery phase, not necessarily the plasma half-life of the perpetrator drug.
Worked Example: Onset of Mechanism-Based Inactivation
Suppose a hypothetical inactivator is maintained at a concentration that produces \(k_{\mathrm{obs}}=0.20\ \mathrm{day}^{-1}\). The enzyme degradation rate is \(k_{\mathrm{deg}}=0.10\ \mathrm{day}^{-1}\), and baseline activity is \(e(0)=1\). Assume the victim drug has \(f_m=0.70\), meaning 70% of its baseline clearance is mediated by this enzyme, with the remaining clearance unaffected. Assume linear pharmacokinetics, unchanged bioavailability, and a quasi-steady relationship between enzyme activity and victim-drug clearance.
The enzyme steady state and onset rate are $$ e_{\mathrm{ss}}=\frac{0.10}{0.10+0.20}=0.3333,\qquad \lambda=0.10+0.20=0.30\ \mathrm{day}^{-1}. $$
At day 7, the enzyme activity is $$ e(7)=0.3333+(1-0.3333)\exp[-0.30(7)] =0.3333+0.6667(0.12246)=0.4150. $$
Under the stated clearance assumptions, the relative clearance is \((1-f_m)+f_m e\), and the same-dose AUC ratio is its reciprocal. Therefore, at day 7, $$ \frac{\mathrm{AUC}(7)}{\mathrm{AUC}_0} =\frac{1}{0.30+0.70(0.4150)} =\frac{1}{0.5905}\approx1.694. $$
The day-7 quasi-steady estimate is an AUC about 1.694 times baseline, or 169.4% of baseline. At enzyme steady state, the ratio would be \(1/[0.30+0.70(0.3333)]=1.875\). Thus the predicted interaction has not yet reached its eventual magnitude by day 7. The time to complete 90% of the change in enzyme activity is \(\ln(10)/0.30=7.675\) days; this describes approach to the activity asymptote, not a universal clinical wash-in duration.
Induction, AUC Ratios, and Washout
Induction is represented as an increase in synthesis. For constant induction with multiplier \(s>1\) and no concurrent inactivation, activity approaches \(s\) with time constant \(1/k_{\mathrm{deg}}\). If inducer concentration changes, \(s(t)\) can change as well. For example, an indirect-response model might specify \(s(t)=1+E_{\max}I_u(t)/(EC_{50}+I_u(t))\). When inducer concentration decays gradually after dosing stops, synthesis stimulation also wanes gradually; treating washout as an instantaneous switch is an approximation.
For a victim drug whose baseline clearance fraction mediated by the affected enzyme is \(f_m\), assume that this pathway's clearance is proportional to active enzyme and other clearance routes remain unchanged. Then $$ \frac{CL(t)}{CL_0}=(1-f_m)+f_m e(t),\qquad \frac{\mathrm{AUC}(t)}{\mathrm{AUC}_0}\approx\frac{1}{(1-f_m)+f_m e(t)}. $$
The AUC relationship is a quasi-steady approximation for the same victim-drug dose when bioavailability is unchanged and pharmacokinetics are linear. It is useful when enzyme activity changes slowly relative to victim-drug disposition and the AUC is evaluated over a period in which activity is approximately stable. If activity changes meaningfully during the dosing interval, the concentration-time course must instead be obtained from a pharmacokinetic model with time-varying clearance.
Worked Example: Induction Onset and the Quasi-Steady AUC Ratio
Consider a hypothetical victim drug with \(f_m=0.70\). An inducer increases enzyme synthesis threefold, so \(s=3\), and there is no enzyme inactivation. Let the enzyme degradation rate be chosen as \(k_{\mathrm{deg}}=\ln(2/0.870)/14\approx0.05946\ \mathrm{day}^{-1}\). This gives an enzyme activity of \(e(14)=3-2\exp(-14k_{\mathrm{deg}})=2.130\), starting from baseline activity \(e(0)=1\).
At day 14, the quasi-steady AUC ratio is $$ \frac{\mathrm{AUC}(14)}{\mathrm{AUC}_0} =\frac{1}{0.30+0.70(2.130)} =\frac{1}{1.791} \approx0.5583. $$
Under these assumptions, the estimated victim-drug AUC at day 14 is about 55.83% of baseline. This is not an estimate that the enzyme activity itself is 55.83% of baseline: enzyme activity is 2.130 times baseline, while the unaffected clearance fraction limits the total clearance change.
If the inducer is then stopped and its effect on synthesis is approximated as ending immediately, enzyme activity recovers from \(e_0=2.130\). After 7 days, the predicted activity is $$ e(7)=1+(2.130-1)\exp[-0.05946(7)] =1+1.130(0.6594)\approx1.745. $$
The corresponding quasi-steady AUC ratio is $$ \frac{\mathrm{AUC}}{\mathrm{AUC}_0} =\frac{1}{0.30+0.70(1.745)} =\frac{1}{1.5215}\approx0.6572. $$
The estimated AUC has moved toward baseline, but remains about 65.72% of baseline after 7 days in this simplified recovery scenario. The estimate depends on the assumed immediate return of synthesis to baseline; a slowly declining inducer concentration would require a time-varying \(s(t)\).
Time-Varying Perpetrator Exposure and Model Checks
For time-varying synthesis and inactivation, the activity equation remains linear but its coefficients change over time. Define \(\lambda(t)=k_{\mathrm{deg}}+k_{\mathrm{inact}}(t)\). Multiplying the differential equation by its integrating factor yields the solution below. It shows that current activity depends on both the initial enzyme amount and the history of synthesis and inactivation.
The first term is the surviving contribution of enzyme present at baseline; the second is enzyme synthesized over time, discounted by subsequent loss. This makes clear why plasma washout alone does not specify recovery: residual perpetrator exposure can continue inactivation or induction, and the enzyme already lost or induced takes time to turn over.
When both induction and inactivation operate, use both terms in the model rather than treating either mechanism as the whole interaction. Under constant effects, the steady activity is \(k_{\mathrm{deg}}s/(k_{\mathrm{deg}}+k_{\mathrm{obs}})\). A rise in synthesis and an increase in inactivation can partly offset, fully offset, or dominate one another; the net effect cannot be inferred from the mechanism names alone.
- Check the time scale. Compare perpetrator concentration change and enzyme turnover. If perpetrator washout is not fast relative to turnover, an abrupt washout assumption can misstate recovery.
- Check the activity trajectory. A single predicted steady state cannot explain measurements that show continued onset or recovery. Compare observations across multiple times, not only at one endpoint.
- Check the clearance mapping. The simple AUC equation assumes unchanged non-enzyme clearance and proportionality between enzyme activity and the relevant clearance pathway. If these fail, the ratio may be biased.
- Check identifiability. Sparse clinical observations may not distinguish a slow enzyme turnover rate from a slowly declining perpetrator concentration. Independent concentration and enzyme-activity information can help separate these explanations.
Choosing the Appropriate Prediction
A static DDI calculation, such as the earlier material on fraction metabolized and multiple clearance routes, is appropriate when perpetrator effects and enzyme activity can reasonably be treated as constant over the period of interest. The time-dependent model adds onset and recovery by predicting \(e(t)\) before translating it into clearance. A full PK model goes further by using time-varying clearance directly to predict concentrations and AUC under changing conditions.
| Approach | What it represents | Main limitation |
|---|---|---|
| Static clearance or AUC ratio | A fixed enzyme effect and fixed victim-drug clearance | Does not describe onset or recovery |
| Enzyme turnover model plus quasi-steady ratio | Changing enzyme activity and approximate AUC effect at selected times | Assumes activity changes slowly enough for the clearance-to-AUC approximation |
| PK model with time-varying clearance | Victim-drug concentrations as clearance changes over time | Requires appropriate PK structure and sufficient information to estimate or specify time-varying effects |
A common mistake is to assume that stopping an inducer or inactivator immediately restores baseline enzyme activity. The perpetrator concentration may decline quickly, but enzyme abundance recovers according to synthesis and degradation. For example, after induction stops in the model above, the excess activity decays as \((e_0-1)\exp(-k_{\mathrm{deg}}t)\), rather than disappearing at the moment of the last dose.
These models also have limits. They assume a meaningful enzyme activity scale, specified turnover rates, and a known mapping from activity to victim-drug clearance. They do not automatically account for changing bioavailability, nonlinear victim-drug pharmacokinetics, multiple enzymes with different turnover, or changing disease state. The simple equations are therefore a transparent mechanistic starting point; model structure should expand when those factors are relevant to the decision.
Check Your Understanding
Work each problem using the assumptions stated. Solutions follow the questions.
- For \(k_{\mathrm{deg}}=0.08\ \mathrm{day}^{-1}\), \(s=2.5\), and no inactivation, what are the steady-state enzyme activity and the time to reach 90% of the activity change from baseline?
- An inactivator produces \(k_{\mathrm{obs}}=0.12\ \mathrm{day}^{-1}\) while \(k_{\mathrm{deg}}=0.08\ \mathrm{day}^{-1}\). Starting at baseline, calculate steady-state activity.
- After induction stops, activity is \(e_0=2.0\) and \(k_{\mathrm{deg}}=0.10\ \mathrm{day}^{-1}\). What is activity after 10 days?
- For a victim drug with \(f_m=0.60\) and enzyme activity \(e=1.5\), calculate the quasi-steady same-dose AUC ratio. State one assumption needed for this calculation.
Solutions. (1) \(e_{\mathrm{ss}}=s=2.5\). Ninety percent of the change is reached when \(1-\exp(-k_{\mathrm{deg}}t)=0.90\), so \(t=\ln(10)/0.08=28.78\) days. (2) \(e_{\mathrm{ss}}=0.08/(0.08+0.12)=0.4000\). (3) \(e(10)=1+(2.0-1)\exp[-0.10(10)]=1+\exp(-1)=1.368\). (4) The ratio is \(1/[0.40+0.60(1.5)]=1/1.30=0.7692\), or 76.92% of baseline. For example, this requires unchanged bioavailability and linear pharmacokinetics, with enzyme activity sufficiently stable over the AUC period.